Low Molecular Weight Iron Dextran Increases Fibroblast Growth Factor-23 Concentration, Together With Parathyroid Hormone Decrease in Hemodialyzed Patients

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 2, 2012, Pages 146-151

  Hryszko, Tomasz ^a   Rydzewska Rosolowska, Alicja ^a   Brzosko, Szymon ^a   Koc Zorawska, Ewa ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bone metabolism; Fibroblast growth factor 23; Hemodialysis; Low molecular weight iron dextran; Parathyroid hormone

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR 23; IRON DEXTRAN; PARATHYROID HORMONE; PHOSPHATE; PROCOLLAGEN TYPE I AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHATES; PROCOLLAGEN; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84859164618     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.01037.x     Document Type: Article

References (30)

1. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-8.
2. Shimada T, Hasegawa H, Yamazaki Y etal. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
3. Krajisnik T, Bjorklund P, Marsell R etal. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-31.
4. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V etal. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8.
5. Liu S, Tang W, Zhou J etal. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.
6. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005;146:5358-64.
7. Isakova T, Gutierrez OM, Smith K etal. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011;26:584-91.
8. Koiwa F, Kazama JJ, Tokumoto A etal. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9:336-9.
9. Fliser D, Kollerits B, Neyer U etal. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-8.
10. Gutierrez OM, Mannstadt M, Isakova T etal. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-92.
11. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010;25:3983-9.
12. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009;94:2332-7.
13. Shimizu Y, Tada Y, Yamauchi M etal. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009;45:814-6.
14. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-145.
15. Locatelli F, Aljama P, Barany P etal. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47.
16. Takeda Y, Komaba H, Goto S etal. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011;33:421-6.
17. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009;150:4835-45.
18. Durham BH, Joseph F, Bailey LM, Fraser WD. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 2007;44:463-6.
19. Khosravi A, Cutler CM, Kelly MH etal. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab 2007;92:2374-7.
20. Angelopoulos NG, Goula A, Rombopoulos G etal. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 2006;24:138-45.
21. Van de Vyver FL, Visser WJ, D'Haese PC, De Broe ME. Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant 1990;5:781-7.
22. Komaba H, Goto S, Fujii H etal. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010;77:232-8.
23. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010;77:211-8.
24. Wang H, Yoshiko Y, Yamamoto R etal. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008;23:939-48.
25. Sitara D, Kim S, Razzaque MS etal. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008;4:e1000154.
26. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572-8.
27. Weinberg ED. Iron availability and infection. Biochim Biophys Acta 2009;1790:600-5.
28. Nishi H, Nii-Kono T, Nakanishi S etal. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005;101:c94-99.
29. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J etal. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070-8.
30. Kalantar-Zadeh K, Kuwae N, Regidor DL etal. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80.